Literature DB >> 12467807

Simultaneous repair of pectus excavatum and congenital heart disease over the past 30 years.

Tomomi Hasegawa1, Masahiho Yamaguchi, Yoshihiro Ohshima, Naoki Yoshimura, Shigeteru Oka, Yoshio Ootaki.   

Abstract

OBJECTIVE: Pectus excavatum may be present in patient requiring operations for cardiac defects. The study was undertaken in order to assess our simultaneous repairs of pectus excavatum and congenital heart disease over past 30 years.
METHODS: Between 1970 and 2000, 12 patients underwent simultaneous repair of pectus excavatum and congenital heart disease. Six of 12 patients had ventricular septal defects as cardiac malformations (subgroup A). Operative technique, after the intracardiac procedure using cardiopulmonary bypass, consists of total subperichondrial resection of deformed costal cartilages, transection of deformed portion of the sternum in 2-3 points, and fixation of the sternum in elevated position using two Kirschner wires and a bridge external traction. Postoperative catheterization was performed in five of 12 patients (subgroup B). We evaluated the operative data, the improvement of pectus deformity and right ventricular performance retrospectively. The operative data in subgroup A were compared with those in recent random patients with ventricular septal defects only or with pectus excavatum only (control groups).
RESULTS: There was no operative death and non-serious complications were seen in nine patients (atelectasis in six, superficial wound infection in two, chylothorax in one). Pectus deformities improved with the drop of vertebral index postoperatively. The mean total operative time and postoperative drainage in subgroup A were 128.4% and 123.7%, respectively of those in the ventricular septal defect control group. The mean perioperative bleeding in subgroup A was more than the sum of those in control groups. Right ventricular end-diastolic (RVEDVI), end-systolic (RVESVI), stroke (RVSVI) volume indices and ejection fraction (RVEF) in subgroup B tended to increase after surgery. In particular, there were significant increases of RVEDVI (35%, P<0.05) and RVSVI (77%, P<0.01).
CONCLUSION: Simultaneous cardiac and pectus repairs were performed successfully without serious complications. Moreover, simultaneous repair resulted in an improvement of right ventricular performance with significant increases of RVEDVI and RVSVI.

Entities:  

Mesh:

Year:  2002        PMID: 12467807     DOI: 10.1016/s1010-7940(02)00571-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Simultaneous minimally invasive surgery for pectus excavatum and recurrent pneumothorax.

Authors:  Korkut Bostanci; Serdar Evman; Mustafa Yuksel
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-07-06

2.  Simultaneous repair of pectus excavatum and pulmonary valve implantation years after complete repair of tetralogy of Fallot.

Authors:  Eylem Tuncer; Ali Can Vuran; Arda Ozyuksel; Ali Yeginsu; Hakan Ceyran
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-01

3.  Simultaneous repair of congenital heart defects and pectus excavatum in young children.

Authors:  Junke Wang; Quan Wang; Zhengxia Pan
Journal:  Pediatr Surg Int       Date:  2018-01-05       Impact factor: 1.827

4.  Combined Bentall and modified Ravitch procedures in a patient with Marfan syndrome.

Authors:  Bhuvnesh Kansara; Ajmer Singh; Samir Girotra; K S Iyer
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-01

5.  The Nuss procedure for pectus excavatum during atrial septal defect closure through a minimal right oblique infra-axillary thoracotomy: A case report.

Authors:  Guangxian Yang; Xicheng Deng; Yifeng Yang; Jinhua Wang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

6.  Simultaneous repair of pectus excavatum and congenital heart disease without cardiopulmonary bypass or sternal osteotomy.

Authors:  Yong Sun; Peng Zhu; Shao-Yi Zheng
Journal:  J Cardiothorac Surg       Date:  2014-10-16       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.